In contrast to the eQTL direction of effect, there is evidence that SEMA5B expression is downregulated in Alzheimer’s disease brains as reported by the Agora platform (https://agora.ampadportal.org/genes) and within our post-hoc analyses, further suggesting a change over the course of disease. Here, SEMA5B is linked to Alzheimer disease.